While justifying high prices by the high risk of failure of new drugs, the industry consistently reports higher profits than any other industry, 17% vs 3.1% for all the other industries on the Fortune 500 list – hardly a sign of high risk. The high profits reflect the exorbitant prices, particularly in the US, where, unlike most countries, there is no governmental mechanism to regulate drug prices.